信立泰(002294.SZ)SAL0137药品临床试验申请获受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein(a) levels [1] Group 1 - The clinical trial application for SAL0137 has been officially accepted, marking a significant milestone for the company's research and development efforts [1] - SAL0137 is an oral small molecule drug developed by the company, which holds independent intellectual property rights for this product [1] - The application submitted by the company specifically targets the treatment of elevated lipoprotein(a), indicating a focus on addressing cardiovascular-related conditions [1]